

**NEUTRA CORP.**

2500 CityWest Blvd Ste 150-161  
Houston, TX 77042

---

307-228-1488  
info@neutrainc.com

## Quarterly Report

For the period ending October 31, 2025 (the "Reporting Period")

### **Outstanding Shares**

The number of shares outstanding of our Common Stock was:

3,042,899,124 as of December 15, 2025 (Current Reporting Period Date or More Recent Date)

3,042,899,124 as of October 31, 2025 (Current Reporting Period Date or More Recent Date)

2,917,899,124 as of January 31, 2025 (Most Recent Completed Fiscal Year End)

### **Shell Status**

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933, Rule 12b-2 of the Exchange Act of 1934 and Rule 15c2-11 of the Exchange Act of 1934):

Yes: ☐ No: ☒

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: ☐ No: ☒

### **Change in Control**

Indicate by check mark whether a Change in Control<sup>4</sup> of the company has occurred during this reporting period:

Yes: ☐ No: ☒

---

<sup>4</sup> "Change in Control" shall mean any events resulting in:

(i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;

(ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;

(iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or

(iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

**1) Name and address(es) of the issuer and its predecessors (if any)**

In answering this item, provide the current name of the issuer and names used by predecessor entities, along with the dates of the name changes.

Neutra Corp

Current State and Date of Incorporation or Registration: Wyoming on August 16, 2019

Standing in this jurisdiction: (e.g. active, default, inactive): Active

Prior Incorporation Information for the issuer and any predecessors during the past five years:

Neutra Corp. was incorporated in Florida on January 11, 2011. On October 5, 2015, we reincorporated from Florida to Nevada. On August 16, 2019 we reincorporated from Nevada to Wyoming.

Describe any trading suspension or halt orders issued by the SEC or FINRA concerning the issuer or its predecessors since inception:

None

List any stock split, dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

None

Address of the issuer's principal executive office:

2500 CityWest Blvd, Ste 150-161  
Houston, TX 77042

Address of the issuer's principal place of business:

☒ *Check if principal executive office and principal place of business are the same address:*

Same

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

No: ☒ Yes: ☐ If Yes, provide additional details below:

No

**2) Security Information**

**Transfer Agent**

Name: Transhare Corporation

Phone: 303-662-1112

Email: [info@transhare.com](mailto:info@transhare.com)

Address: 17755 US Hwy 19 N, Clearwater, FL 33764

**Publicly Quoted or Traded Securities:**

*The goal of this section is to provide a clear understanding of the share information for its publicly quoted or traded equity securities. Use the fields below to provide the information, as applicable, for all outstanding classes of securities that are publicly traded/quoted.*

Trading symbol:

NTRR

Exact title and class of securities outstanding:

Common Stock

CUSIP:

64129C303

Par or stated value:

\$0.001

Total shares authorized:	<u>Unlimited as of date: October 31, 2025</u>
Total shares outstanding:	<u>3,042,899,124 as of date: October 31, 2025</u>
Total number of shareholders of record:	<u>11 as of date: October 31, 2025</u>

Please provide the above-referenced information for all other publicly quoted or traded securities of the issuer.

**Other classes of authorized or outstanding equity securities that do not have a trading symbol:**

The goal of this section is to provide a clear understanding of the share information for its other classes of authorized or outstanding equity securities (e.g., preferred shares that do not have a trading symbol). Use the fields below to provide the information, as applicable, for all other authorized or outstanding equity securities.

Exact title and class of the security:	<u>Preferred stock</u>
Par or stated value:	<u>\$0.001</u>
Total shares authorized:	<u>20,000,000 as of date: October 31, 2025</u>
Total shares outstanding: Series A convertible preferred stock	<u>50,000 as of date: October 31, 2025</u>
Total number of shareholders of record:	<u>1 as of date: October 31, 2025</u>
Total shares outstanding: Series B convertible preferred stock	<u>10,000 as of date: October 31, 2025</u>
Total number of shareholders of record:	<u>1 as of date: October 31, 2025</u>
Total shares outstanding: Series C convertible preferred stock	<u>40,000 as of date: October 31, 2025</u>
Total number of shareholders of record:	<u>1 as of date: October 31, 2025</u>
Total shares outstanding: Series E convertible preferred stock	<u>1,000,000 as of date: October 31, 2025</u>
Total number of shareholders of record:	<u>1 as of date: October 31, 2025</u>
Total shares outstanding: Series F convertible preferred stock	<u>1,00,000 as of date: October 31, 2025</u>
Total number of shareholders of record:	<u>1 as of date: October 31, 2025</u>
Total shares outstanding: Series G convertible preferred stock	<u>0 as of date: October 31, 2025</u>
Total number of shareholders of record:	<u>0 as of date: October 31, 2025</u>

Please provide the above-referenced information for all other classes of authorized or outstanding equity securities.

**Security Description:**

The goal of this section is to provide a clear understanding of the material rights and privileges of the securities issued by the company. Please provide the below information for each class of the company's equity securities, as applicable:

**For common equity, describe any dividend, voting and preemption rights.**

We are authorized to issue unlimited shares of common stock, with a par value of \$0.001.. All shares of common stock have one vote per share on all matters including election of directors, without provision for cumulative voting. The common stock is not redeemable and has no conversion or preemptive rights. In the event of liquidation of the Company, the holders of common stock will share equally in any balance of the Company's assets available for distribution to them after satisfaction of creditors and preferred shareholders, if any. The holders of the Company's common are entitled to equal dividends and distributions per share with respect to the common stock when, as and if, declared by the Board of Directors from funds legally available.

**For preferred stock, describe the dividend, voting, conversion, and liquidation rights as well as redemption or sinking fund provisions.**

**Series A Preferred Stock.** Our Series A Preferred Stock rank is subordinate to all shares of common stock and do not have voting rights. The Series A Preferred Stock has a stated value of \$5 per share. The Series A Preferred Stock was amended on August 1, 2025 to receive no dividend. The holders of the Series A Preferred Stock have the option to convert each share into 800 shares of common stock of the Company.

**Series B Preferred Stock.** Our Series B Preferred Stock rank is subordinate to all shares of common stock and do not have voting rights. The Series B Preferred Stock has a stated value of \$5 per share. The Series B Preferred Stock was amended on August 1, 2025 to receive no dividend. Holders of the Series B Preferred Stock have the option to convert each share into 800 shares of common stock.

**Series C Preferred Stock.** Our Series C Preferred Stock rank is subordinate to all shares of common stock and do not have voting rights. The Series C Preferred Stock has a stated value of \$5 per share. Stock was amended on August 1, 2025 to receive no dividend. Holders of the Series C Preferred Stock have the option to convert each share into 38 shares of common stock.

**Series E preferred stock** The Series E Preferred Stock is subordinated to our common stock. It does not receive dividends and does not participate in equity distributions. The Series E Preferred stock has 2 votes for each outstanding share of common stock in the company.

**Series F preferred stock** The Series F Preferred Stock is subordinated to our common stock and superior to all shares of Preferred Stock. It does not receive dividends and does not participate in equity distributions. The Series F Preferred stock retains 2/3 of the voting rights in the company.

**Series G convertible preferred stock.** The Series G convertible preferred stock has a stated value of \$1.00 per share, carries no voting rights and earns dividends of 8% per annum on the stated value of the stock. The Series G convertible preferred stock is redeemable at the option of the Company during the first nine months it is outstanding at a premium of between 3% and 33% depending on the date of redemption. After the stock has been outstanding for nine months, it is convertible into common stock of the Company at a 29% discount to the market value of the common stock.

**Describe any other material rights of common or preferred stockholders.**

None

**Describe any material modifications to rights of holders of the company’s securities that have occurred over the reporting period covered by this report.**

None

### 3) Issuance History

*The goal of this section is to provide disclosure with respect to each event that resulted in any changes to the total shares outstanding of any class of the issuer’s securities **in the past two completed fiscal years and any subsequent interim period.***

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

**Changes to the Number of Outstanding Shares for the two most recently completed fiscal years and any subsequent period.**

Indicate by check mark whether there were any changes to the number of outstanding shares within the past two completed fiscal years:

No: ☐      Yes: ☒ (If yes, you must complete the table below)

Shares Outstanding <u>Opening Balance:</u>  Date <u>April 30, 2023</u> Common: <u>2,917,899,124</u>  Series A Preferred: <u>50,000</u>  Series B Preferred: <u>10,000</u>  Series C Preferred: <u>40,000</u>  Series E Preferred: <u>1,000,000</u>  Series F Preferred: <u>1,000,000</u>  <u>Series G Preferred: 0</u>	*Right-click the rows below and select “Insert” to add rows as needed.
---	--

Date of Transaction	Transaction type (e.g., new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to.  ***You must disclose the control person(s) for any entities listed.	Reason for share issuance (e.g. for cash or debt conversion) - OR- Nature of Services Provided	Restricted or Unrestricted as of this filing.	Exemption or Registration Type.
<u>10/2/2025</u>	<u>New Issuance</u>	<u>125,000,000</u>	<u>Common</u>	<u>.0002</u>	<u>No</u>	<u>Pacific Capital Markets, LLC. – Zac Logan</u>	<u>Consulting Services</u>	<u>Restricted</u>	<u>Exemption</u>

Shares Outstanding on Date of This Report:

Ending Balance:

Date October 31, 2025

Common: 3,042,899,124

Series A Preferred: 50,000

Series B Preferred: 10,000

Series C Preferred: 40,000

Series E Preferred: 1,000,000

Series F Preferred: 1,000,000

Series G Preferred: 0

**Example:** A company with a fiscal year end of December 31<sup>st</sup> 2023, in addressing this item for its Annual Report, would include any events that resulted in changes to any class of its outstanding shares from the period beginning on January 1, 2022 through December 31, 2023 pursuant to the tabular format above.

**\*\*\*Control persons for any entities in the table above must be disclosed in the table or in a footnote here.**

Use the space below to provide any additional details, including footnotes to the table above:

N/A

## Promissory and Convertible Notes

Indicate by check mark whether there are any outstanding promissory, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities:

No: ☐ Yes: ☐ (If yes, you must complete the table below)

Date of Note Issuance	Outstanding Balance (\$)	Principal Amount at Issuance (\$)	Interest Accrued (\$)	Maturity Date	Conversion Terms (e.g. pricing mechanism for determining conversion of instrument to shares)	Name of Noteholder.  *** You must disclose the control person(s) for any entities listed.	Reason for Issuance (e.g. Loan, Services, etc.)
August 19, 2024	\$47,143	\$50,000	\$4,483	June 18, 2026	No conversion terms	BHAGAT Investments, Inc., Dr. Akash Bhagat	Loan
February 5, 2025	\$125,251	\$125,000	\$0	December 5, 2027	No conversion terms	Stellar Bank	Loan
_____	_____	_____	_____	_____	_____	_____	_____

**\*\*\*Control persons for any entities in the table above must be disclosed in the table or in a footnote here.**

Use the space below to provide any additional details, including footnotes to the table above:

N/A

#### 4) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations. Ensure that these descriptions are updated on the Company's Profile on [www.OTCMarkets.com](http://www.OTCMarkets.com).

Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

Neutra Corp's wholly owned subsidiary, Neutra Life Sciences is a Clinical Research Site Management Organization. As a Clinical Research SMO, it is comprised of multiple clinical research sites with multiple specialties. This includes but aren't limited to, Pediatrics, Pediatric Pulmonology, Urgent Care, Family Medicine, Optometry, Podiatry and Oncology. At these clinical research sites, NLS conducts industry sponsored clinical trials that help provide the data to the industry sponsors to apply for FDA approval.

List any subsidiaries, parent company, or affiliated companies.

The Company's wholly owned subsidiary is Neutra Life Sciences, LLC.

Describe the issuers' principal products or services.

Business development consulting services, and natural and organic nutraceutical medicinal products.

#### 5) Issuer's Facilities

*The goal of this section is to provide investors with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and the extent in which the facilities are utilized.*

In responding to this item, please clearly describe the assets, properties or facilities of the issuer. Describe the location of office space, data centers, principal plants, and other property of the issuer and describe the condition of the properties. Specify if the assets, properties, or facilities are owned or leased and the terms of their leases. If the issuer does not have complete ownership or control of the property, describe the limitations on the ownership.

The Company owns machinery and equipment.

The Company has a corporate off located at 2500 CityWest Blvd Suite 150-161 Houston, Texas 77042. The Company's subsidiary, Neutra Life Sciences leases a corporate suite of 2,814 square feet at 2825 Wilcrest Drive Suite 560 Houston, Texas 77042.

#### 6) All Officers, Directors, and Control Persons of the Company

Using the table below, please provide information, as of the period end date of this report, regarding all officers and directors of the company, or any person that performs a similar function, regardless of the number of shares they own.

In addition, list all individuals or entities controlling 5% or more of any class of the issuer's securities. If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity. Include Company Insiders who own any outstanding units or shares of any class of any equity security of the issuer.

*The goal of this section is to provide investors with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial owners.*

Names of All Officers, Directors, and Control Persons	Affiliation with Company (e.g. Officer Title /Director/Owner of 5% or more)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Names of control person(s) if a corporate entity
---	---	---	------------------------	------------------	---	--

<u>Sydney Jim</u>	<u>Principal Executive Officer and Sold Director</u>	<u>2500 CityWest Blvd Ste 150-161 Houston, TX 770425</u>	<u>20,000,000</u> <u>1,000,000</u>	<u>Common stock</u> <u>Series F Preferred Stock</u>	<u>2%</u> <u>100%</u>	<u>N/A</u> <u>N/A</u>
<u>Gilbert Fung</u>	<u>Board Member</u>	<u>2500 CityWest Blvd Ste 150-161 Houston, TX 77042</u>	<u>N/A</u>	<u>N/A</u>	<u>N/A</u>	<u>N/A</u>
<u>Daniel Chen</u>	<u>Board Member</u>	<u>2500 CityWest Blvd Ste 150-161 Houston, TX 77042</u>	<u>N/A</u>	<u>N/A</u>	<u>N/A</u>	<u>N/A</u>
<u>Amar Raval</u>	<u>Board Member</u>	<u>2500 CityWest Blvd Ste 150-161 Houston, TX 77042</u>	<u>N/A</u>	<u>N/A</u>	<u>N/A</u>	<u>N/A</u>
<u>Cole Munger</u>	<u>Board Member</u>	<u>2500 CityWest Blvd Ste 150-161 Houston, TX 77042</u>	<u>N/A</u>	<u>N/A</u>	<u>N/A</u>	<u>N/A</u>

Confirm that the information in this table matches your public company profile on [www.OTCMarkets.com](http://www.OTCMarkets.com). If any updates are needed to your public company profile, log in to [www.OTCIQ.com](http://www.OTCIQ.com) to update your company profile.

## 7) Legal/Disciplinary History

Identify and provide a brief explanation as to whether any of the persons or entities listed above in Section 6 have, in the past 10 years:

Been the subject of an indictment or conviction in a criminal proceeding or plea agreement or named as a defendant in a pending criminal proceeding (excluding minor traffic violations);

No

Been the subject of the entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, financial- or investment-related, insurance or banking activities;

No

3. Been the subject of a finding, disciplinary order or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, a state securities regulator of a violation of federal or state securities or commodities law, or a foreign regulatory body or court, which finding or judgment has not been reversed, suspended, or vacated;

No

Named as a defendant or a respondent in a regulatory complaint or proceeding that could result in a "yes" answer to part 3 above; or

No

5. Been the subject of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

No

Been the subject of a U.S Postal Service false representation order, or a temporary restraining order, or preliminary injunction with respect to conduct alleged to have violated the false representation statute that applies to U.S mail.

No

Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party to or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

No pending legal proceedings.

## **8) Third Party Service Providers**

Provide the name, address, telephone number and email address of each of the following outside providers. You may add additional space as needed.

Confirm that the information in this table matches your public company profile on [www.OTCMarkets.com](http://www.OTCMarkets.com). If any updates are needed to your public company profile, update your company profile.

Securities Counsel (must include Counsel preparing Attorney Letters).

Name:	<u>Sam Whitley Esq. Whitley LLP Attorneys at Law</u>
Address 1:	<u>24285 Katy Freeway, Suite 300</u>
Address 2:	<u>Katy, Texas 77494</u>
Phone:	<u>(281) 206-0434</u>
Email:	<u>swhitley@whitley-llp.com</u>

### Accountant or Auditor

Name:	<u>Robert J Wilson, CPA</u>
Firm:	<u>Robert J Wilson, CPA</u>
Nature of Services:	<u>Consulting and financial services</u>
Address 1:	<u>563 West Bay Area Blvd., Suite 245</u>
Address 2:	<u>Webster, Texas 77598</u>
Phone:	<u>281-770-9270</u>
Email:	

### Investor Relations

Name:	<u>N/A</u>
Firm:	<u>N/A</u>
Address 1:	<u>N/A</u>
Address 2:	<u>N/A</u>
Phone:	<u>N/A</u>
Email:	<u>N/A</u>

### *All other means of Investor Communication:*

X (Twitter):	<u>@CorpNeutra</u>
Discord:	<u>N/A</u>
LinkedIn	<u><a href="https://www.linkedin.com/company/neutra-corp/">https://www.linkedin.com/company/neutra-corp/</a></u>
Facebook:	<u><a href="https://www.facebook.com/neutracorp">https://www.facebook.com/neutracorp</a></u>
[Other ]	<u>N/A</u>

### Other Service Providers

Provide the name of any other service provider(s) that **that assisted, advised, prepared, or provided information with respect to this disclosure statement**. This includes counsel, broker-dealer(s), advisor(s), consultant(s) or any entity/individual that provided assistance or services to the issuer during the reporting period.

Name:	<u>Zac Logan</u>
Firm:	<u>Pacific Capital Markets, LLC.</u>
Address 1:	<u>4770 Leathers Street</u>
Address 2:	<u>San Diego, CA 92117</u>



Phone: 858-407-9903  
Email: N/A

## 9) Disclosure & Financial Information

This Disclosure Statement was prepared by (name of individual):

Name: Sydney Jim  
Title: Chairman and CEO  
Relationship to Issuer: Chairman and CEO

The following financial statements were prepared in accordance with:

- ☐ IFRS  
☒ U.S. GAAP

The following financial statements were prepared by (name of individual):

Name: Robert J Wilson, CPA  
Title: Consultant firm  
Relationship to Issuer: Service provider

Describe the qualifications of the person or persons who prepared the financial statements:<sup>5</sup>

**Experts in accounting and financial reporting for public and private companies.**

Provide the following qualifying financial statements:

Audit letter, if audited;  
Balance Sheet;  
Statement of Income;  
Statement of Cash Flows;  
Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)  
Financial Notes

### **Financial Statement Requirements:**

Financial statements must be published together with this disclosure statement as one document.  
Financial statements must be "machine readable". Do not publish images/scans of financial statements.  
Financial statements must be presented with comparative financials against the prior FYE or period, as applicable.  
Financial statements must be prepared in accordance with U.S. GAAP or International Financial Reporting Standards (IFRS) but are not required to be audited.

## 10) Issuer Certification

*Principal Executive Officer:*

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

I, Sydney Jim, certify that:

I have reviewed this Disclosure Statement for Neutra Corp.

---

<sup>5</sup> The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS and by persons with sufficient financial skills.

Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and

Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

December 16, 2025

/s/ Sydney Jim

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

*Principal Financial Officer:*

I, Sydney Jim, certify that:

I have reviewed this Disclosure Statement for Neutra Corp.

Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and

Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

December 16, 2025

/s/ Sydney Jim

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

**NEUTRA CORP.**

**CONSOLIDATED BALANCE SHEETS  
(UNAUDITED)**

	<u>October 31, 2025</u>	<u>January 31, 2025</u>
<b>CURRENT ASSETS</b>		
Cash and cash equivalents	\$ 35,582	\$ 36,743
Accounts receivable	160,311	143,011
Total current assets	195,893	179,754
Property and equipment, net	17,890	15,635
<b>TOTAL ASSETS</b>	<u><u>\$ 213,783</u></u>	<u><u>\$ 195,388</u></u>
<b>LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' DEFICIT</b>		
<b>Current Liabilities</b>		
Accounts payable and accrued expenses	\$ 267,539	\$ 568,614
Accounts payable to related party	389,023	493,696
Advances payable	-	3,450
Advances payable to related party	-	12,314
Notes payable, related party	115,200	227,437
Accrued interest payable	-	8,722
Total current liabilities	771,762	1,314,233
Notes payable, related party	-	-
<b>TOTAL LIABILITIES</b>	<u><u>771,762</u></u>	<u><u>1,314,233</u></u>
<b>COMMITMENTS AND CONTINGENCIES</b>		
<b>MEZZANINE EQUITY</b>		
Series G preferred stock; \$1.00 stated value, 0 shares and 35,200 shares issued and outstanding at October 31, 2025 and January 31, 2025, respectively	-	-
<b>STOCKHOLDERS' DEFICIT</b>		
Common stock, \$0.001 par value; unlimited shares authorized; 3,042,899,124 and 2,917,899,124 shares issued and outstanding at October 31, 2025 and January 31, 2025, respectively	2,942,898	2,917,898
Preferred stock, \$0.001 par value; 20,000,000 shares authorized:		
Series A convertible preferred stock; 50,000 shares issued and outstanding at October 31, 2025 and January 31, 2025	50	50
Series B convertible preferred stock; 10,000 and 0 shares issued and outstanding at October 31, 2025 and January 31, 2025	10	10
Series C convertible preferred stock; 40,000 shares issued and outstanding at October 31, 2025 and January 31, 2025	40	40
Series E preferred stock, 1,000,000 shares issued and outstanding at October 31, 2025 and January 31, 2025	1,000	1,000
Series F preferred stock, \$0.001 par value; 1,000,000 shares issued and outstanding at October 31, 2025 and January 31, 2025	1,000	1,000
Additional paid-in capital	7,721,539	7,695,539
Preferred stock subscribed but not issued	1,077,000	150,000
Accumulated deficit	(12,276,516)	(11,885,382)
<b>TOTAL STOCKHOLDERS' DEFICIT</b>	<u><u>(557,979)</u></u>	<u><u>(1,118,845)</u></u>
<b>TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' DEFICIT</b>	<u><u>\$ 213,783</u></u>	<u><u>\$ 195,388</u></u>

The accompanying footnotes are an integral part of these unaudited consolidated financial statements.

**NEUTRA CORP.**  
**CONSOLIDATED STATEMENTS OF OPERATIONS**  
**(UNAUDITED)**

	Three Months Ended October 31,		Nine Months Ended October 31,	
	2025	2024	2025	2024
REVENUE	\$ 351,841	\$ 8,566	\$ 790,068	\$ 67,106
Cost of goods sold	<u>108,765</u>	<u>565</u>	<u>304,649</u>	<u>2,920</u>
Gross margin	<u>243,076</u>	<u>8,001</u>	<u>485,419</u>	<u>64,186</u>
OPERATING EXPENSES				
Depreciation	1,267	0	3,806	1,121
Sales commissions	0	340	0	2,800
General and administrative expenses	<u>112,726</u>	<u>31,443</u>	<u>389,921</u>	<u>131,235</u>
Total operating expenses	<u>113,993</u>	<u>31,783</u>	<u>392,727</u>	<u>135,156</u>
PROFIT/LOSS FROM OPERATIONS	<u>129,083</u>	<u>(23,782)</u>	<u>91,692</u>	<u>(70,970)</u>
OTHER INCOME (EXPENSE)				
Interest expense	<u>(5,784)</u>	<u>(893)</u>	<u>(18,209)</u>	<u>(2,640)</u>
Other Income (Gain from SPA Reversal)	<u>(464,617)</u>	<u>(52)</u>	<u>(464,617)</u>	<u>(52)</u>
Total other income (expense)	<u>(470,401)</u>	<u>(945)</u>	<u>(482,826)</u>	<u>(2,692)</u>
Net income/loss before income taxes	\$ (341,318)	\$ (24,727)	\$ (391,134)	\$ (73,662)
Provision for income taxes	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>
Net Income/Loss	\$ (341,318)	\$ (24,727)	\$ (391,134)	\$ (73,662)
Deemed dividend on Series G convertible preferred stock	<u>—</u>	<u>—</u>	<u>—</u>	<u>—</u>
Net loss available to common shareholders	<u>\$ (341,318)</u>	<u>\$ (24,727)</u>	<u>\$ (319,134)</u>	<u>\$ (73,662)</u>
Net loss per common share	<u>\$ (0.00)</u>	<u>\$ (0.00)</u>	<u>\$ (0.00)</u>	<u>\$ (0.00)</u>
Weighted average shares outstanding - basic and diluted	<u>2,080,029,387</u>	<u>2,917,899,124</u>	<u>2,641,562,625</u>	<u>2,917,899,124</u>

The accompanying footnotes are an integral part of these unaudited consolidated financial statements.

**NEUTRA CORP.**  
**CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT**  
**(UNAUDITED)**

	<b>Common stock</b>		<b>Series A Convertible Preferred Stock</b>		<b>Series B Preferred Stock</b>		<b>Series C Preferred Stock</b>		<b>Series E Preferred Stock</b>		<b>Series F Preferred Stock</b>		<b>Additional paid-in capital</b>	<b>Accumulated Deficit</b>	<b>Stock subscribed but not issued</b>	<b>Total Equity (Deficit)</b>
	<b>Shares</b>	<b>Par</b>	<b>Shares</b>	<b>Par</b>	<b>Shares</b>	<b>Par</b>	<b>Shares</b>	<b>Par</b>	<b>Shares</b>	<b>Par</b>	<b>Shares</b>	<b>Par</b>				
<b>Balance, January 31, 2025</b>	2,917,899,124	\$ 2,917,899	50,000	\$ 50	10,000	\$ 10	40,000	\$ 40	1,000,000	\$ 1,000	1,000,000	\$ 1,000	\$ 7,696,539	\$ (11,885,382)	\$ 150,000	\$ (1,246,778)
Preferred stock to be issued for acquisition	—	—	—	—	—	—	—	—	—	—	—	—	—	—	900,000	900,000
Common stock to be issued for services	—	—	—	—	—	—	—	—	—	—	—	—	—	—	27,000	27,000
Net Loss	—	—	—	—	—	—	—	—	—	—	—	—	—	(947,480)	—	(947,480)
<b>Balance, April 30, 2025</b>	2,917,899,124	\$ 2,917,899	50,000	\$ 50	10,000	\$ 10	40,000	\$ 40	1,000,000	\$ 1,000	1,000,000	\$ 1,000	\$ 7,696,539	\$ (12,960,795)	\$ 1,077,000	\$ (1,267,258)
Net loss	—	—	—	—	—	—	—	—	—	—	—	—	—	17,351	—	17,351
<b>Balance, July 31, 2025</b>	2,917,899,124	\$ 2,917,898	50,000	\$ 50	10,000	\$ 10	40,000	\$ 40	1,000,000	\$ 1,000	1,000,000	\$ 1,000	\$ 7,696,539	\$ (12,943,444)	\$ 1,077,000	\$ (1,249,907)
Net loss	125,000,000	25,000	—	—	—	—	—	—	—	—	—	—	—	(366,134)	—	(366,134)
<b>Balance, October 31, 2025</b>	<u>3,042,899,124</u>	<u>\$ 2,942,898</u>	<u>50,000</u>	<u>\$ 50</u>	<u>10,000</u>	<u>\$ 10</u>	<u>40,000</u>	<u>\$ 40</u>	<u>1,000,000</u>	<u>\$ 1,000</u>	<u>1,000,000</u>	<u>\$ 1,000</u>	<u>\$ 7,696,539</u>	<u>\$ (12,251,516)</u>	<u>\$ 1,077,000</u>	<u>\$ (557,979)</u>
<b>Balance, January 31, 2024</b>	2,917,899,124	\$ 2,917,898	50,000	\$ 50	10,000	\$ 10	40,000	\$ 40	1,000,000	\$ 1,000	1,000,000	\$ 1,000	\$ 7,751,839	\$ (11,692,515)	\$ 50,000	\$ (970,678)
Net loss	—	—	—	—	—	—	—	—	—	—	—	—	—	(16,352)	—	(16,352)
<b>Balance, April 30, 2024</b>	2,917,899,124	2,917,898	50,000	50	10,000	10	40,000	40	1,000,000	1,000	1,000,000	1,000	7,751,839	(11,708,867)	50,000	(987,030)
Net loss	—	—	—	—	—	—	—	—	—	—	—	—	—	(32,583)	—	(32,583)
<b>Balance, July 31, 2024</b>	2,917,899,124	\$ 2,917,898	50,000	\$ 50	10,000	\$ 10	40,000	\$ 40	1,000,000	\$ 1,000	1,000,000	\$ 1,000	\$ 7,751,839	\$ (11,741,450)	\$ 50,000	\$ (1,019,613)
Net loss	—	—	—	—	—	—	—	—	—	—	—	—	—	(24,727)	—	(24,727)
<b>Balance, October 31, 2024</b>	<u>2,917,899,124</u>	<u>\$ 2,917,898</u>	<u>50,000</u>	<u>\$ 50</u>	<u>10,000</u>	<u>\$ 10</u>	<u>40,000</u>	<u>\$ 40</u>	<u>1,000,000</u>	<u>\$ 1,000</u>	<u>1,000,000</u>	<u>\$ 1,000</u>	<u>\$ 7,751,839</u>	<u>\$ (11,766,177)</u>	<u>\$ 50,000</u>	<u>\$ (1,044,340)</u>

The accompanying footnotes are an integral part of these unaudited consolidated financial statements.

**NEUTRA CORP.**  
**CONSOLIDATED STATEMENTS OF CASH FLOWS**  
**(UNAUDITED)**

	<b>Nine Months Ended October 31,</b>	
	<b>2025</b>	<b>2024</b>
<b>CASH FLOW FROM OPERATING ACTIVITIES:</b>		
Net loss	\$ (366,134)	\$ (73,662)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation	3,806	1,121
Stock compensation	927,000	-
Changes in operating assets and liabilities		
Accounts receivable	(160,311)	98
Accounts payable and accrued liabilities	(233,682)	57,057
Accounts payable to related party	(125,235)	18,450
Accrued interest payable	(10,247)	2,639
<b>NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES</b>	<b>35,197</b>	<b>5,703</b>
<b>CASH FLOWS FROM INVESTING ACTIVITIES</b>		
Purchase of fixed assets	-	-
<b>NET CASH USED IN INVESTING ACTIVITIES</b>	<b>-</b>	<b>-</b>
<b>CASH FLOWS FROM FINANCING ACTIVITIES</b>		
Proceeds from advance from related party	-	-
Repayments on notes payable	-	-
<b>NET CASH PROVIDED BY FINANCING ACTIVITIES</b>	<b>-</b>	<b>-</b>
<b>NET CHANGE IN CASH AND CASH EQUIVALENTS</b>	<b>35,197</b>	<b>5,703</b>
Cash and cash equivalents at beginning of period	385	1,632
Cash and cash equivalents at end of period	<u>\$ 35,582</u>	<u>\$ 7,335</u>
Cash paid during the period for:		
Interest	<u>\$ -</u>	<u>\$ -</u>
Taxes	<u>\$ -</u>	<u>\$ -</u>
Noncash investing and financing transactions:		
Conversion of Series G preferred stock	<u>\$ -</u>	<u>\$ -</u>
Expenses paid on the Company's behalf	<u>\$ -</u>	<u>\$ 38,493</u>

The accompanying footnotes are an integral part of these unaudited consolidated financial statements.

**NEUTRA CORP.**  
**NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS**  
**October 31 2025**

**Note 1. Background Information**

Neutra Corp. was incorporated in Nevada on January 11, 2011, to market and participate in the nutraceutical space by bringing products derived from all natural and organic origins. Along with participating in the actual nutraceutical products, we plan to research and bring new technology to the nutraceutical space. Nutraceutical natural medicine is an alternative system that focuses on natural remedies and the body's vital ability to heal and maintain itself. One of the nutraceutical sub-markets is the new thriving medical cannabis market, in which we intend to participate. We intend to entrust the manufacturing to a nutraceutical contractor to private label all of our products and to sell them under our unique brand. We have established a fiscal year end of January 31.

On February 18, 2025, the Company entered into a securities purchase agreement with Neutra Life Sciences, LLC ("NLS"), a Texas limited liability corporation, which was controlled 100% by Sydney Jim, the Company's Chairman and CEO. Pursuant to the terms of the agreement, the Company acquired 1,000,000 shares, representing 100% of the outstanding equity securities of Neutra Life Sciences, for \$900,000 payable in 180,000 shares of a convertible preferred stock that has not yet been designated. The convertible preferred stock will be convertible into common shares at a ratio of one share of preferred stock for 50 common shares. As NLS was controlled by the controlling shareholder of the Company, the transaction was considered a combination of entities under common control under Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") 805, with assets and liabilities of NLS being recognized on the Company's balance sheet at carryover basis in accordance with ASC 805. The results of operations and cash flows of NLS are included in the Company's consolidated financial statements since the incorporation date of NLS.

NLS began operations in August 2024. Neutra Life Sciences principal services are clinical research services include full turn-key research conducting services such as: Study Start-up, IRB Submission, Contracts & Budgets negotiations, Clinical Research Staff, Clinica Study Inventory and management, Regulatory Services, Patient Recruitment and other clinical research services.

**Note 2. Going Concern**

For the nine months ended October 31, 2025, the Company had a net loss of \$366,136. As of October 31, 2025, the Company has negative working capital of \$557,979. We have generated limited revenues to date and our activities have been primarily limited to developing our business plan and research and development of products. We will not have the necessary capital to fully develop or execute our business plan until we are able to secure additional financing. There can be no assurance that such financing will be available on suitable terms. We need to raise additional funds in order to implement our business plan. Our current cash on hand is insufficient to commercialize our products or fully develop our business strategy. If we are unable to raise adequate additional funds or if those funds are not available on terms that are acceptable to us, we will not be able to execute our business plan and we may cease operations.

These factors raise a substantial doubt about the Company's ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the possible inability of the Company to continue as a going concern.

The Company does not have the resources at this time to repay its credit and debt obligations, make any payments in the form of dividends to its shareholders or fully implement its business plan. Without additional capital, the Company will not be able to remain in business.

Management has plans to address the Company's financial situation as follows:

In the near term, management plans to continue to focus on raising the funds necessary to implement the Company's business plan. Management will continue to seek out debt financing to obtain the capital required to meet the Company's financial obligations. There is no assurance, however, that lenders will continue to advance capital to the Company or that the new business operations will be profitable. The possibility of failure in obtaining additional funding and the potential inability to achieve profitability raises doubts about the Company's ability to continue as a going concern.

In the long term, management believes that the Company's projects and initiatives will be successful and will provide cash flow to the Company that will be used to finance the Company's future growth. However, there can be no assurances that the Company's planned activities will be successful, or that the Company will ultimately attain profitability. The Company's long-term viability depends on its ability to obtain adequate sources of debt or equity funding to meet current commitments and fund the continuation of its business operations, and the ability of the Company to achieve adequate profitability and cash flows from operations to sustain its operations.

**Note 3. Significant Accounting Policies**

The significant accounting policies that the Company follows are:

### **Interim Financial Statements**

The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial information and with the instructions to Form 10-Q and Regulation S-X. Accordingly, the consolidated financial statements do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included and such adjustments are of a normal recurring nature. These consolidated financial statements should be read in conjunction with the consolidated financial statements for the fiscal year ended January 31, 2025 and notes thereto and other pertinent information contained in our annual report.

The results of operations for the three-month period ended October 31, 2025 are not necessarily indicative of the results to be expected for the full fiscal year ending January 31, 2026.

### **Basis of Presentation**

The unaudited consolidated financial statements and related disclosures have been prepared pursuant to the rules and regulations of the SEC. The unaudited consolidated financial statements have been prepared using the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America ("GAAP").

### **Consolidated Financial Statements**

The unaudited consolidated financial statements of the Company include the accounts of the Company and its wholly owned subsidiaries, Diamond Anvil Designs, LLC Deity Corporation, Vivis Corporation (Vivis), and Neutra Life Sciences, LLC, from the date of their formations or acquisition. Significant intercompany transactions have been eliminated in consolidation.

### **Use of Estimates**

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

### **Cash and Cash Equivalents**

All cash, other than held in escrow, is maintained with a major financial institution in the United States. Deposits with this bank may exceed the amount of insurance provided on such deposits. Temporary cash investments with an original maturity of three months or less are considered to be cash equivalents. Cash and cash equivalents were \$50,871 and \$36,743 at July 31 2025 and January 31, 2025, respectively.

### **Accounts Receivable**

Accounts receivable is carried at their estimated collectible amounts. Accounts receivable is periodically evaluated for collectability based on past credit history with customers and their current financial condition. The Company had an allowance of \$160,311 at October 31, 2025 and \$0 at January 31, 2025.

### **Inventory**

Inventory is comprised of packaging and supplies and at times raw materials. Inventory is valued at cost, based on the average cost method, unless and until the net realizable value for the inventory is lower than cost, in which case an allowance is established to reduce the valuation to the net realizable value. As of October 31, 2025 and January 31, 2025, the Company recognized an inventory impairment loss of \$0.

### **Property and Equipment, net**

Property and equipment consist of equipment used to manufacture the Company's products and is presented at cost. Depreciation is recognized over the useful life of the equipment on a straight-line basis over five and three years beginning when the asset is put in service.

### **Impairment of long-lived assets**

Long-lived assets, including fixed assets and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the long-lived asset may not be recoverable. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. If it is determined that an impairment loss has occurred, the loss is measured as the amount by which the carrying amount of



the long-lived asset exceeds its fair value. The Company determined that there was no impairment of long-lived assets during the periods ended October 31, 2025 and January 31, 2025.

## **Revenue Recognition**

The Company recognizes revenue in accordance with ASC Topic 606, Revenue From Contracts With Customers. Revenues are recognized when control of the promised goods or services is transferred to the customer in an amount that reflects the consideration the Company expects to be entitled to in exchange for transferring those goods or services. Revenue is recognized based on the following five step model:

- Identification of the contract with a customer
- Identification of the performance obligations in the contract
- Determination of the transaction price
- Allocation of the transaction price to the performance obligations in the contract
- Recognition of revenue when, or as, the Company satisfies a performance obligation

Product sales are recognized all of the following criteria are satisfied: (i) a contract with an end user exists which has commercial substance; (ii) it is probable the Company will collect the amount charged to the end user; and (iii) the Company has completed its performance obligation whereby the end user has obtained control of the product. A contract with commercial substance exists once the Company receives and accepts a purchase order or once it enters into a contract with an end user. If collectability is not probable, the sale is deferred and not recognized until collection is probable or payment is received. Control of products typically transfers when title and risk of ownership of the product has transferred to the customer. Payment is received before shipment of the product. Net revenues comprise gross revenues less customer discounts and allowances, actual and expected returns. Shipping charges billed to customers are included in net sales. Various taxes on the sale of products to customers are collected by the Company as an agent and remitted to the respective taxing authority. These taxes are presented on a net basis and recorded as a liability until remitted to the respective taxing authority. The Company allows for customers to return unopened products within 10 days in certain limited circumstances. There have been no refunds processed for returned product.

The Company also provides consulting services of business development. The revenue from this contract is recognized over time as the customer receives the benefit of the services under the contract.

The Company's subsidiary NLS also generates revenue from performing clinical trial services to pharmaceutical companies.

For the nine months ended October 31, 2025, revenue from consulting income from business development consulting services totaled \$0, and revenue from clinical trial services totaled \$790,068.

## ***Contract Costs***

Costs incurred to obtain a customer contract are not material to the Company. The Company elected to apply the practical expedient to not capitalize contract costs to obtain contracts with a duration of one year or less, which are expensed and included within cost of goods and services.

## ***Cost of Sales***

Cost of sales includes all of the costs to purchase and assemble the Company's products, medical records and supplies, payroll costs of doctors and staff conducting clinical trials and patient stipend expense. Products are manufactured for the Company by third-party contractors, such costs represent the amounts invoiced by the contractors. Additionally, shipping costs are included in Cost of Sales in the Statements of Operations.

## **Earnings (Loss) per Common Share**

We compute basic and diluted earnings per common share amounts in accordance with ASC Topic 260, *Earnings per Share*. The basic earnings (loss) per common share are calculated by dividing our net income available to common shareholders by the weighted average number of common shares outstanding during the year. The diluted earnings (loss) per common share are calculated by dividing our net income (loss) available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted as of the first of the year for any potentially dilutive debt or equity. There are no dilutive shares outstanding for any periods reported.

## **Mezzanine equity**

Where ordinary or preferred shares are determined to be conditionally redeemable upon the occurrence of certain events that are not solely within the control of the issuer, and upon such event, the shares would become redeemable at the option of the holders, they are

classified as ‘mezzanine equity’ (temporary equity). The purpose of this classification is to convey that such a security may not be permanently part of equity and could result in a demand for cash, securities or other assets of the entity in the future.

### Subsequent events

The Company follows the guidance in Section 855-10-50 of the FASB Accounting Standards Codification for the disclosure of subsequent events. The Company will evaluate subsequent events through the date when the financial statements were issued. Pursuant to ASU 2010-09 of the FASB Accounting Standards Codification, the Company as an SEC filer considers its financial statements issued when they are widely distributed to users, such as through filing them on EDGAR.

### Recently Adopted Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the effect of recently issued standards that are not yet effective will not have a material effect on its financial position or results of operations upon adoption.

ASC Topic 280, “*Segment Reporting*,” requires annual and interim reporting for an enterprise’s operating segments and related disclosures about its products, services, geographic areas and major customers. An operating segment is defined as a component of an enterprise that engages in business activities from which it may earn revenues and expenses, and about which separate financial information is regularly evaluated by the chief operating decision maker in deciding how to allocate resources. In November 2023, the FASB issued ASU No. 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosure.” The ASU updates reportable segment disclosure requirements, primarily through requiring enhanced disclosures about significant segment expenses and information used to assess segment performance. The amendments do not change how segments are determined, aggregated, or how thresholds are applied to determine reportable segments. The Company adopted ASU No. 2023-07 during the year ended January 31, 2025.

In November 2024, the FASB issued ASU 2024-03, *Disaggregation of Income Statement Expenses (DISE)*, requiring additional disclosure of the nature of expenses included in the income statement. The new standard requires disclosures about specific types of expenses included in the expense captions presented on the face of the income statement as well as disclosures about selling expenses. The amendments in this update are effective for annual periods beginning after December 15, 2026 and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact of our pending adoption of this standard on our consolidated financial statements.

### Note 4. Property and equipment, net

Property and equipment consist of the following:

	<u>October 31, 2025</u>	<u>January 31, 2025</u>
Equipment	\$ 257,226	\$ 252,352
Total property and equipment	257,226	252,352
Less: accumulated depreciation	(239,336)	(236,717)
Property and equipment, net	<u>\$ 17,890</u>	<u>\$ 15,635</u>

For the nine months ended October 31, 2025 and 2024, the Company recognized depreciation expense of \$3,806 and \$1,269, respectively.

### Note 5. Related Party Transactions

During the nine months ended October 31, 2025 and 2024, we incurred salary expense of \$58,010 to our CEO, Sydney Jim. In addition, we incurred commission expenses of \$25,265 and \$2,460 during the nine months ended October 31, 2025 and 2024 to Mr. Jim is owed a total of \$82,436 accrued commissions as of October 31, 2025. During the nine months ended October 31, 2025 and 2024, Mr. Jim paid expenses of \$5,159 and \$12,888, respectively, on behalf of the Company.

As of October 31, 2025 and January 31, 2025, we owed Mr. Jim, or entities controlled by him, \$630,685 and \$474,823 which is recorded on the balance sheet in “Accounts Payable – Related Party”, respectively, and \$6,545 in “Advances payable to related party”. This balance includes the commissions payable to Mr. Jim described above.

On August 1, 2025, the Company entered into a Securities Purchase Agreement Reversal and Debt Settlement Agreement with VIVIS Corporation, a Texas Corporation which Sydney Jim, the Company’s CEO, had controlling interest in that will produce hemp and cannabis products. Neutra Corp did not fulfill the contracted terms of the original Securities Purchase Agreement therefore Sydney Jim has agreed to settle the debt of \$295,975, which related to VIVIS Corporation by payment of the equipment named in the Securities Purchase Agreement Reversal and Debt Settlement Agreement.

On February 18, 2025, the Company entered into a securities purchase agreement with Neutra Life Sciences, LLC, a Texas corporation which the Sydney Jim, the Company’s CEO, owns 100% of the outstanding equity securities. The transaction combined entities under

common control as Sydney Jim controls both entities. Pursuant to the terms of the agreement, the Company acquired 1,000,000 shares, representing 100% of the outstanding equity securities of Neutra Life Sciences, a Texas Limited Liability Corporation, for \$900,000 payable in 180,000 shares of the Company's convertible preferred stock. As of October 31, 2025, the 180,000 shares of preferred stock have not yet been designated, and the fair value is included in subscriptions payable on the Company's consolidated balance sheet. The convertible preferred stock will be convertible into an aggregate of 9,000,000 shares of common stock.

On August 16, 2024, Neutra Life Sciences, LLC and Sydney Jim, the Company's CEO entered into an independent contractor agreement whereby the contractor shall serve as CEO of Neutra Life Sciences, LLC, for a period of nine months. As compensation for his services, the consultant will receive a monthly fee of \$12,000 and 100,000,000 shares of common stock. Also, he will receive 4.5% of gross revenue from all the projects he closes. If at any time he is no longer affiliated with the Company, the royalty amount will drop to 2.5% of gross revenue. Furthermore, he will receive 15% of gross revenue from VIVIS Corp and 2.5% of revenue of all Industry Sponsored Studies Awarded he closes and 5% of all clinical research sites referred to and closed by him for Neutra Life Sciences. Lastly, as acting President and Chief Executive Officer, he will receive 20% of net profits on a semi-annual basis if NLS has at least one fiscal quarter of operational cash reserves. A year-end bonus can be established by the President and CEO which can include cash plus restricted common stock. As of July 31 2025, the consultant is owed a total of 100,000,000 shares of common stock with a fair value of \$20,000, based on the common stock price on the grant date. The shares have not been issued to date, and the fair value is included in subscriptions payable on the Company's consolidated balance sheet.

On March 11, 2022, the Company entered into a loan agreement for \$60,000 of proceeds with the holder of the Company's Series A and B preferred stock. The loan is unsecured and bears interest at 6%. The Company will make monthly payments of \$4,240 per month beginning in April 2022 through the maturity at June 18, 2023. As of October 31, 2025 and January 31, 2025, the note principal balance was \$54,156 and accrued interest was \$9,642 and \$8,722, respectively. The Company has not made all required monthly payments under the note agreement to date and the loan is currently in default.

During the year ended January 31, 2022, the Company acquired the assets of Deity Corporation, a Texas corporation which the Sydney Jim, the Company's CEO, had a controlling interest in that will produce hemp and cannabis products. The transaction was considered an asset acquisition, as there were no operations of Deity Corporation prior to the transaction. The Company received the formulas for certain hemp and cannabis-based products and a website to market the products that will be produced. In exchange, the Company will pay to Mr. Jim 60% of the revenue from Deity Corporation sales until a total of \$250,000 is reached, at which point the Company will pay 20% of Deity Corporation revenue to Mr. Jim.

#### **Note 6. Advances and Notes Payable**

As of October 31, 2025 and January 31, 2025, we had amounts due under advances of \$3,450 at each period. These advances are not collateralized, non-interest bearing and are due on demand.

On August 1, 2025, the Liang On Call, PLLC note for \$60,000 of proceeds with the holder of the Company's Series A and B stock have been settled in the Securities Purchase Agreement Reversal and Debt Settlement Agreement

On March 11, 2022, the Company entered into a loan agreement for \$60,000 of proceeds with the holder of the Company's Series A and B preferred stock. The loan is unsecured and bears interest at 6%. The Company will make monthly payments of \$4,240 per month beginning in April 2022 through the maturity at June 18, 2023. As of October 31, 2025 and January 31, 2025, the note principal balance was \$54,156 and accrued interest was \$9,642 and \$8,722, respectively. The Company has not made all required monthly payments under the note agreement to date and the loan is currently in default.

As part of the securities purchase agreement with Neutra Life Sciences, LLC, the Company assumed a promissory note, dated February 5, 2025, with a third party for a total principal of \$125,000. The Company will pay 9.5% per annum, until the total principal is paid in full. The note will be repaid in 31 monthly consecutive principal and interest payments of \$4,445.44 each, beginning May 5, 2025. During the three months ended October 31 2025, the Company repaid \$3,030. As of October 31 2025, the balance owed on the note was \$121,970. Accrued interest on the note was \$0 as of October 31 2025.

As part of the securities purchase agreement with Neutra Life Sciences, LLC, the Company assumed a promissory note, dated August 19, 2024, with a third party for a total principal of \$50,000. The Company will pay 20% per annum, until the total principal is paid in full. The note will be repaid in consecutive monthly installments of principal and interest payments of \$2,857.14 each, beginning in November, 2024. During the three months ended October 31 2025, the Company repaid \$2,857.14. As of October 31, 2025, the balance owed on the note was \$47,143. Accrued interest on the note was \$4,483 as of October 31, 2025.

#### **Note 7. Shareholders' Equity**

**Series A Preferred Stock.** In January 2020, our board of directors designated 50,000 shares of our preferred stock as Series A Preferred Stock which rank subordinate to all shares of common stock and do not have voting rights. The Series A Preferred Stock has a stated value of \$5 per share. The Series A Preferred Stock is entitled to receive dividends of 10% of the net profit of VIVIS Corporation. The holders of the Series A Preferred Stock have the option to convert each share into 800 shares of common stock of the Company. As of October 31 2025 and January 31, 2025, there are 50,000 shares of Series A Preferred Stock outstanding.

***Series B Preferred Stock.*** In July 2020, our board of directors designated 10,000 shares of our preferred stock as Series B Preferred Stock which rank subordinate to all shares of common stock and do not have voting rights. The Series B Preferred Stock has a stated value of \$5 per share. The Series B Preferred Stock is entitled to receive dividends of 0.4% of the net profit of VIVIS Corporation. Holders of the Series B Preferred Stock have the option to convert each share into 800 shares of common stock. During the year ended January 31, 2021, the Company subscribed 10,000 shares of Series B Preferred Stock for cash proceeds of \$50,000. The shares were issued during the year ended January 31, 2022. As of October 31, 2025 and January 31, 2025, there are 10,000 shares of Series B Preferred Stock outstanding.

***Series C Preferred Stock.*** In November 2020, our board of directors designated 40,000 shares of our preferred stock as Series C Preferred Stock which rank subordinate to all shares of common stock and do not have voting rights. The Series C Preferred Stock has a stated value of \$5 per share. The Series C Preferred Stock is entitled to receive dividends of 10% of the net profit of VIVIS Corporation. After the Series C Preferred Stock has received cumulative dividends of \$500,000, the dividend rate will reduce to 1%. Holders of the Series C Preferred Stock have the option to convert each share into 38 shares of common stock. During the year ended January 31, 2021, the Company subscribed 40,000 shares of Series B Preferred Stock for cash proceeds of \$200,000. The shares were issued during the year ended January 31, 2022. As of October 31, 2025 and January 31, 2025, there are 40,000 shares of Series C Preferred Stock outstanding.

#### ***Series E preferred stock issued for services***

On November 13, 2015, our board of directors designated 1,000,000 shares of our preferred stock as Series E Preferred Stock. The Series E Preferred Stock is subordinated to our common stock. It does not receive dividends and does not participate in equity distributions. The Series E Preferred stock has 2 votes for each outstanding share of common stock in the company. As of October 31, 2025 and January 31, 2025, there are 1,000,000 shares Series E Preferred Stock outstanding. Dividends, when, as and if declared by the Board of Directors, shall be paid out of funds at the time legally available for such purposes.

#### ***Series F preferred stock issued for services***

The Series F Preferred Stock is subordinated to our common stock and superior to all shares of Preferred Stock. It does not receive dividends and does not participate in equity distributions. The Series F Preferred stock retains 2/3 of the voting rights in the company. During the year ended January 31, 2021, the Company issued 1,000,000 shares of Series F Preferred Stock to Sydney Jim, our CEO, in exchange for services. As of the date of this report, there are 1,000,000 shares Series F Preferred Stock outstanding. As of October 31, 2025 and January 31, 2025, there are 1,000,000 shares of Series F Preferred Stock outstanding.

#### ***Series G convertible preferred stock***

During the year ended January 31, 2024, the holders of the Series G convertible preferred stock converted 35,200 shares and accrued dividends of \$1,408 into 174,323,810 shares of common stock. The conversions were in accordance with the terms of the agreement and no gain or loss was recognized. As of October 31, 2025 and January 31, 2025, there were no shares of Series G convertible preferred stock outstanding.

#### **Stock Subscription**

On February 23, 2022, the Company sold 10,000 shares of preferred stock not yet designated for cash proceeds of \$50,000.

On February 18, 2025, the Company entered into a securities purchase agreement with Neutra Life Sciences, LLC, a Texas corporation which the Sydney Jim, the Company's CEO, owns 100% of the outstanding equity securities. The transaction combined entities under common control as Sydney Jim controls both entities. Pursuant to the terms of the agreement, the Company acquired 1,000,000 shares, representing 100% of the outstanding equity securities of Neutra Life Sciences, a Texas Limited Liability Corporation, for \$900,000 payable in 180,000 shares of the Company's convertible preferred stock. As of October 31, 2025, the 180,000 shares of preferred stock have not yet been designated, and the fair value is included in subscriptions payable on the Company's consolidated balance sheet. The preferred stock will be convertible into 9,000,000 shares of common stock.

On August 16, 2024, Neutra Life Sciences, LLC and Sydney Jim, the Company's CEO entered into an independent contractor agreement whereby the contractor shall serve as CEO of Neutra Life Sciences, LLC, for a period of six months. As compensation for his services, the consultant will receive a monthly fee of \$12,000 and 100,000,000 shares of common stock. As of October 31, 2025, the consultant is owed a total of 100,000,000 shares with a fair value of \$20,000, based on the common stock price on the grant date. The shares have not been issued to date, and the fair value is included in subscriptions payable on the Company's consolidated balance sheet.

On August 16, 2024, Neutra Life Sciences, LLC and a contractor entered into an independent contractor agreement whereby the contractor shall serve as Director of Clinical Operations of the Company, for a period of six months as compensation for his services, the consultant will receive a bi-monthly fee of \$5,000 and 30,000,000 shares of common stock. As of October 31, 2025, the consultant is owed a total of 30,000,000 shares with a fair value of \$6,000, based on the common stock price on the grant date. The shares have not been issued to date, and the fair value is included in subscriptions payable on the Company's consolidated balance sheet.

On August 16, 2024, Neutra Life Sciences, LLC and a contractor entered into an independent contractor agreement whereby the contractor shall serve as Administrator of the Company's clinical operations, for a period of nine months as compensation for his services, the consultant will receive a bi-monthly fee of \$1,750 and 5,000,000 shares of common stock. As of October 31, 2025, the

consultant is owed a total of 5,000,000 shares with a fair value of \$1,000, based on the common stock price on the grant date. The shares have not been issued to date, and the fair value is included in subscriptions payable on the Company's consolidated balance sheet.

On October 2, 2025, Neutra Corp and a contractor entered into an independent contractor agreement whereby the Company shall serve as a consultant for the Company, for a period of twelve months as compensation for his services, the consultant will receive a bi-125,000,000 shares of common stock in which at the time of issuance the stock price was \$.0002. This at the time was a value of \$25,000.00. The shares have been booked with the transfer agent but have not been issued to date, and the fair value is included in subscriptions payable on the Company's consolidated balance sheet.

## **Note 8. Commitments and Contingencies**

### Legal Contingencies

From time to time, we may be involved in various disputes and litigation matters that arise in the ordinary course of business. The Company is currently not a party to any material legal proceedings.

### Commitments

The Company follows ASC 450-20, *Loss Contingencies*, to report accounting for contingencies. Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated.

As discussed in more detail in Note 5, the Company agreed to pay 60% of all revenue from Deity Corporation to Sydney Jim, the Company's CEO, up until a total of \$250,000 is paid to Mr. Jim, at which point he will be entitled to 20% of revenue from Deity Corporation.

On August 16, 2024, Neutra Life Sciences, LLC and Sydney Jim, the Company's CEO entered into an independent contractor agreement whereby the contractor shall serve as CEO of Neutra Life Sciences, LLC, for a period of six months. As compensation for his services, the consultant will receive a monthly fee of \$12,000 and 100,000,000 shares of common stock. Also, he will receive 4.5% of gross revenue from all the projects he closes. If at any time he is no longer affiliated with the Company, the royalty amount will drop to 2.5% of gross revenue. Furthermore, he will receive 15% of gross revenue from VIVIS Corp and 2.5% of revenue of all Industry Sponsored Studies Awarded he closes and 5% of all clinical research sites referred to and closed by him for Neutra Life Sciences. Lastly, as acting President and Chief Executive Officer, he will receive 20% of net profits on a semi-annual basis if NLS has at least one fiscal quarter of operational cash reserves. A year-end bonus can be established by the President and CEO which can include cash plus restricted common stock. As of October 31, 2025, the consultant is owed a total of 100,000,000 shares of common stock with a fair value of \$20,000, based on the common stock price on the grant date. The shares have not been issued to date, and the fair value is included in subscriptions payable on the Company's consolidated balance sheet.

On August 16, 2024, Neutra Life Sciences, LLC and a contractor entered into an independent contractor agreement whereby the contractor shall serve as Director of Clinical Operations of the Company, for a period of six months. As compensation for his services, the consultant will receive a bi-monthly fee of \$5,000 and 30,000,000 shares of common stock. Also, the contractor will receive 2% of gross revenue from the clinical research visit revenue for as long as the contractor is providing services for NLS. If at any time the contractor is no longer affiliated with NLS, the royalty amount will drop to 1% of gross revenue from the clinical research visit revenue. In addition, all contracted clinical research sites referred to and closed by the Contractor, the Contractor will receive a Quarterly Bonus Compensation of 4% of clinical research visit revenue. Lastly, as acting Director of Clinical Operations of NLS, the Contractor will receive 5% of net profits on a semi-annual basis if NLS has at least 1 fiscal quarter of operational cash reserves. A year-end bonus can be established by the President and CEO which can include cash plus restricted common stock. As of October 31, 2025, the consultant is owed a total of 30,000,000 shares with a fair value of \$6,000, based on the common stock price on the grant date. The shares have not been issued to date, and the fair value is included in subscriptions payable on the Company's consolidated balance sheet.

On August 16, 2024, Neutra Life Sciences, LLC and a contractor entered into an independent contractor agreement whereby the contractor shall serve as Administrator of the Company's clinical operations, for a period of six months. As compensation for his services, the consultant will receive a bi-monthly fee of \$1,750 and 5,000,000 shares of common stock. Also, a year-end bonus can be established by the President and CEO which can include cash plus restricted common stock. As of October 31, 2025, the consultant is owed a total of 5,000,000 shares with a fair value of \$1,000, based on the common stock price on the grant date. The shares have not been issued to date, and the fair value is included in subscriptions payable on the Company's consolidated balance sheet.

There were no other known commitments or contingencies as of October 31, 2025 and January 31, 2025.

## **Note 9. Subsequent Events**

Management has evaluated events through December 16, 2025, the date these financial statements were available for issuance, and noted no events requiring disclosures.